Stoke Therapeutics Reports Positive 4-Year Zorevunersen Data, Advances Phase 3, and Secures $80.7M in Q1 ATM Sales

summarizeSummary

Stoke Therapeutics announced Q1 2026 financial results, including a revenue decline but a strong cash position of $411.0 million, bolstered by $80.7 million from ATM sales. The company also reported positive 4-year clinical data for zorevunersen in Dravet syndrome and confirmed its Phase 3 study is on track for NDA submission.

check_boxKey Events

• Positive 4-Year Clinical Data for Zorevunersen

  New 4-year longitudinal data from Phase 1/2a open-label extension studies for zorevunersen in Dravet syndrome showed statistically significant improvements in cognition and behavior, alongside continued durability in seizure reductions. The investigational medicine was generally well tolerated, with some patients treated for over 5 years.

• Phase 3 EMPEROR Study Progress Confirmed

  Enrollment of approximately 150 patients into the global Phase 3 EMPEROR study is expected to complete in June 2026, supporting a data readout in mid-2027. These data are anticipated to complete the rolling U.S. New Drug Application (NDA) submission planned to initiate in Q1 2027.

• Q1 2026 Financial Results and Cash Runway

  The company reported a net loss of $50.0 million for Q1 2026, compared to net income of $112.9 million in Q1 2025, primarily due to a decrease in revenue from $158.6 million to $6.2 million following the 2025 recognition of an IP license. Stoke Therapeutics ended the quarter with $411.0 million in cash, cash equivalents, and marketable securities, extending its operational runway into 2028.

• Significant Capital Raised via ATM Program

  During the first quarter of 2026, Stoke Therapeutics raised approximately $80.7 million through the selective use of its At-The-Market (ATM) facility by selling 2.6 million shares of common stock. This capital raise contributes to the company's strong financial position.

auto_awesomeAnalysis

Stoke Therapeutics reported Q1 2026 financial results, including a significant revenue decrease primarily due to the prior year's recognition of an IP license. Despite this, the company maintains a strong cash position of $411.0 million, extending its operational runway into 2028, partly due to raising $80.7 million through its At-The-Market (ATM) facility. Critically, the company announced compelling 4-year longitudinal data for zorevunersen in Dravet syndrome, demonstrating statistically significant improvements in cognition, behavior, and sustained seizure reductions. The Phase 3 EMPEROR study remains on track for enrollment completion in June 2026, with a mid-2027 data readout expected to finalize the rolling U.S. NDA submission. This combination of strong clinical progress for its lead asset and a solid financial foundation significantly de-risks the company's near-term outlook and commercialization path.